As for patients with other tumors such as gastric cancer, breast cancer, pancreatic carcinoma, prostate cancer, hepatocellular carcinoma, lung cancer, colorectal cancer, bladder cancer, gliomas, pituitary adenomas, acoustic neuromas, craniopharyngiomas, cavernous hemangiomas, and schwannomas, their serum EGFL6 concentrations were all significantly lower than those of patients with benign meningioma (Table 1). This evidence concerns the gene EGFL6 and urinary bladder carcinoma.